Martina M.D. Flammer Sells 37,828 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 37,828 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $2,973,659.08. Following the completion of the transaction, the insider now directly owns 100,165 shares in the company, valued at approximately $7,873,970.65. This trade represents a 27.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, February 6th, Martina M.D. Flammer sold 33,055 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total transaction of $2,674,149.50.
• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The shares were sold at an average price of $68.72, for a total transaction of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total value of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Stock Performance

INSM traded down $0.29 during trading on Wednesday, hitting $79.60. 1,389,754 shares of the company traded hands, compared to its average volume of 1,907,916. The firm has a market cap of $14.24 billion, a P/E ratio of -14.34 and a beta of 1.11. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a one year low of $21.92 and a one year high of $82.04. The stock’s fifty day moving average is $73.15 and its 200 day moving average is $73.16.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently modified their holdings of INSM. Steward Partners Investment Advisory LLC raised its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC purchased a new stake in Insmed during the third quarter valued at about $30,000. GAMMA Investing LLC increased its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares in the last quarter. Spire Wealth Management bought a new stake in shares of Insmed in the fourth quarter valued at approximately $47,000. Finally, Exchange Traded Concepts LLC boosted its holdings in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 627 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on INSM. Truist Financial reissued a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Morgan Stanley lifted their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Guggenheim increased their price objective on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Stifel Nicolaus lifted their target price on Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.60.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.